(L8I7) Lyxor NASDAQ-100 Daily - Ratings and Ratios
Leveraged Equity Investments, NASDAQ-100 Exposure, Inverse Equity Options
Description: L8I7 Lyxor NASDAQ-100 Daily
The Lyxor UCITS NASDAQ-100 Daily Leverage ETF (XETRA:L8I7) is a German-originated exchange-traded fund that offers leveraged exposure to the NASDAQ-100 Index, a benchmark that tracks the performance of the 100 largest and most liquid non-financial stocks listed on the NASDAQ stock exchange. This ETF is designed for traders seeking to amplify their returns, providing 2 times the daily return of the underlying index.
From a technical analysis perspective, the ETF is currently trading at €1191.40, above its 20-day and 200-day Simple Moving Averages (SMA20 and SMA200) of €1154.81 and €1154.34, respectively, indicating a positive short-term and long-term trend. The 50-day Simple Moving Average (SMA50) is at €1073.28, further supporting the bullish trend. The Average True Range (ATR) is at 2.26%, indicating moderate volatility. Given the current price action and technical indicators, it is likely that the ETF will continue to trend upwards, potentially reaching new 52-week highs.
Fundamentally, the Lyxor UCITS NASDAQ-100 Daily Leverage ETF has Assets Under Management (AUM) of €620.01 million, indicating a reasonable level of liquidity and investor interest. As the ETF is linked to the NASDAQ-100 Index, its performance is closely tied to the technology and growth sectors, which have been exhibiting strong growth trends in recent years. With the ongoing advancements in technology and the increasing dominance of the FAANGs (Facebook, Apple, Amazon, Netflix, and Alphabet), it is likely that the NASDAQ-100 Index will continue to perform well, driving the ETFs returns.
Forecasting the ETFs future performance, we can expect the Lyxor UCITS NASDAQ-100 Daily Leverage ETF to continue to trend upwards, driven by the ongoing growth in the technology and growth sectors. Using a combination of technical and fundamental analysis, we can expect the ETF to potentially reach €1300 in the near term, representing a 9% increase from current levels. However, traders should be cautious of the potential risks associated with leveraged ETFs, including the impact of volatility and the potential for significant losses if the underlying index were to decline.
Additional Sources for L8I7 ETF
L8I7 ETF Overview
Market Cap in USD | 1,102m |
Category | Trading - Leveraged/Inverse Equity |
TER | 0.60% |
IPO / Inception | 2006-06-27 |
L8I7 ETF Ratings
Growth Rating | 54.1 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -8.03 |
Analysts | - |
Fair Price Momentum | 1109.58 EUR |
Fair Price DCF | - |
L8I7 Dividends
Currently no dividends paidL8I7 Growth Ratios
Growth Correlation 3m | 93.6% |
Growth Correlation 12m | 12.6% |
Growth Correlation 5y | 63.2% |
CAGR 5y | 19.83% |
CAGR/Max DD 5y | 0.32 |
Sharpe Ratio 12m | 0.94 |
Alpha | -18.50 |
Beta | 2.039 |
Volatility | 25.88% |
Current Volume | 0.5k |
Average Volume 20d | 1.1k |
Stop Loss | 1195.8 (-3.5%) |
As of July 11, 2025, the stock is trading at EUR 1239.20 with a total of 457 shares traded.
Over the past week, the price has changed by +0.13%, over one month by +6.83%, over three months by +45.77% and over the past year by +2.14%.
Partly, yes. Based on ValueRay´s Analyses, Lyxor NASDAQ-100 Daily (XETRA:L8I7) is currently (July 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 54.05 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of L8I7 is around 1109.58 EUR . This means that L8I7 is currently overvalued and has a potential downside of -10.46%.
Lyxor NASDAQ-100 Daily has no consensus analysts rating.
According to our own proprietary Forecast Model, L8I7 Lyxor NASDAQ-100 Daily will be worth about 1331.5 in July 2026. The stock is currently trading at 1239.20. This means that the stock has a potential upside of +7.45%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1331.5 | 7.4% |